
Peter G. Collin, MD
Advertisement
Collin is a second-year infectious diseases fellow at Beth Israel Deaconess Medical Center.
Articles by Peter G. Collin, MD


The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Zoliflodacin Emerges as a First-in-Class Oral Option Against Drug-Resistant Gonorrhea
2
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
3
FDA Approves Zoliflodacin for Uncomplicated Urogenital Gonorrhea
4
Top Infectious Disease News Stories Week of December 6 - December 12
5

